Delivery Order SPE2DR25D3802-SPE2DR26F6VDV
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,541.08 for Restasis 0.05% Eye Emulsion (30-count units) on May 6, 2025, with an ultimate completion date of May 7, 2025. This firm fixed-price delivery order represents a non-competitive procurement under a larger indefinite delivery contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $3,561.92 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply...
- The Defense Logistics Agency awarded a $6,297.40 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% eye emulsion (60-unit package). This non-set-aside, competitively awarded contract features firm fixed pricing and is scheduled for completion by July 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger...
- The Defense Logistics Agency awarded a $4,871.29 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30 single-dose units) on December 17, 2025, with an ultimate completion date of December 18, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,013.75 to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (30 single-use vials) on January 8, 2026, with an ultimate completion date of January 9, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. AmerisourceBergen Drug Corp operates as...
- The Defense Logistics Agency awarded a delivery order valued at $3,916.15 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,340.35 to AmerisourceBergen Drug Corp for supply of Restasis 0.05% Eye Emulsion (60 count) on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded Amerisourcebergen Drug Corp a delivery order valued at $4,142.48 on January 6, 2026, for the supply of Restasis 0.05% eye emulsion (30-unit packs). This is a firm fixed-price, non-set-aside contract with a completion date of January 7, 2026, and performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order valued at $18,986.97 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors....
- The Defense Logistics Agency awarded a $12,777.96 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will be completed by July 29, 2025, with work performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DR25D3802Indefinite Delivery Contract
- SPE2DR25D3802-SPE2DR26F6VDVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,923.36 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (60 units) on January 16, 2026, with an ultimate completion date of January 20, 2026. This is a firm fixed-price, non-set-aside contract with performance taking place in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc., which holds a significant indefinite delivery contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the vehicle for this pharmaceutical supply award. AmerisourceBergen operates as a major pharmaceutical distributor and healthcare solutions provider, supplying critical medical commodities to military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The parent organization, Cencora, Inc., competes on a full and open basis for federal contracts and maintains extensive experience delivering a diverse array of pharmaceutical products across multiple therapeutic domains to support Defense Health Agency operations and broader military healthcare programs globally. This specific delivery order for Restasis eye emulsion represents a routine pharmaceutical supply transaction within the broader framework of the company's substantial medical supply relationship with the federal government.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 1/15/26 |